ClinicalTrials.gg
CompletedNCT04440163Updated Apr 18, 2023Results posted

MenABCWY Noninferiority Study in Healthy Participants ≥10 to <26 Years of Age

A Phase 3 interventional study of MenABCWY and Saline in Meningococcal Vaccine, sponsored by Pfizer. Completed at 78 sites in 5 countries. Open to participants aged 10 Years to 25 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-04-18.

Sponsored by Pfizer · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
2,431
Allocation
Randomized
Ages
10 Years to 25 Years
Sex
All
01

Study summary

The aim of this study is to determine the immunologic noninferiority of MenABCWY to licensed vaccines Trumenba and MenACWY-CRM (Menveo) by assessing the safety and immunogenicity of MenABCWY and the comparators in both ACWY-naïve and ACWY-experienced healthy participants ≥10 to \<26 years of age.

02

Conditions studied

  • Meningococcal Vaccine
03

In context

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
10 Years to 25 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subject aged >=10 and \<26 years at the time of randomization.
  • Healthy subject as determined by medical history, physical examination, and judgment of the investigator.
  • Negative urine pregnancy test for all female subjects.
  • ACWY-naïve participants: Participants who have never received a prior dose of a meningococcal vaccine containing ACWY serogroups.
  • ACWY-experienced participants: Participants who have received not more than 1 prior dose, no sooner than 4 years prior to the date of randomization of Menactra or Menveo.

Exclusion criteria

Exclusion Criteria:

  • Previous vaccination with any meningococcal group B vaccine, any purely polysaccharide (nonconjugate) meningococcal vaccine, or monovalent/bivalent meningococcal vaccine.- Subjects receiving any allergen immunotherapy with a non-licensed product or receiving allergen immunotherapy with a licensed product and are not on stable maintenance doses.
  • A known or suspected defect of the immune system that would prevent an immune response to the vaccine, such as subjects with congenital or acquired defects in B cell function, those receiving chronic systemic (oral, intravenous, or intramuscular) therapy, or those receiving therapy. Subjects in the United States with terminal complement deficiency are excluded from participation in this study.
  • Significant neurological disorder or history of seizure (excluding simple febrile seizure).
  • Current chronic use of systemic antibiotics.
  • Participation in other studies involving drug(s) or investigational vaccine(s) within 28 days prior to study entry and/or during study participation.
  • Any neuroinflammatory or condition, including, but not limited to, transverse myelitis, uveitis, optic neuritis, and multiple sclerosis.
  • History of microbiologically proven disease caused by N meningitidis or Neisseria gonorrhoeae.
  • Receipt of any blood products, including immunoglobulin, within 6 months before the first study vaccination.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
2,431 participants (actual)

Study arms

  • Experimental
    1-Immuno Subset (ACWY Naive,MenABCWY/Saline)

    ACWY Naive subjects, MenABCWY/Saline

    Biological: MenABCWY · Biological: Saline

  • Experimental
    2-Immuno Subset (ACWY Naive, Trumenba/MenACWY-CRM)

    ACWY Naive subjects, Trumenba/MenACWY-CRM

    Biological: Trumenba · Biological: MenACWY-CRM

  • Experimental
    3-Immuno Subset (ACWY Experienced,MenABCWY/Saline)

    ACWY Experienced subjects, MenABCWY/Saline

    Biological: MenABCWY · Biological: Saline

  • Experimental
    4-Immuno Subset (ACWY Experienced,Trumenba/MenACWY-CRM)

    ACWY Experienced subjects, Trumenba/MenACWY-CRM

    Biological: Trumenba · Biological: MenACWY-CRM

  • Experimental
    5-Safety Subset (ACWY Naive,MenABCWY/Saline)

    ACWY Naive subjects, MenABCWY/Saline

    Biological: MenABCWY · Biological: Saline

  • Experimental
    6-Safety Subset (ACWY Naive,Trumenba/MenACWY-CRM)

    ACWY Naive subjects, Trumenba/MenACWY-CRM

    Biological: Trumenba · Biological: MenACWY-CRM

  • Experimental
    7-Safety Subset (ACWY Experienced,MenABCWY/Saline)

    ACWY Experienced subjects, MenABCWY/Saline

    Biological: MenABCWY · Biological: Saline

  • Experimental
    8-Safety Subset (ACWY Experienced,Trumenba/MenACWY-CRM)

    ACWY Experienced subjects, Trumenba/MenACWY-CRM

    Biological: Trumenba · Biological: MenACWY-CRM

Interventions

  • BiologicalMenABCWY

    N meningitidis groups A, B, C, W, and Y vaccine

  • BiologicalSaline

    Placebo

  • BiologicalTrumenba

    Drug pages: MenB-FHbp vaccine · 4CMenB vaccine

    Bivalent recombinant lipoprotein 2086 vaccine

  • BiologicalMenACWY-CRM

    Meningococcal group A, C, W-135, and Y conjugate vaccine

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving At Least 4-Fold Rise in Serum Bactericidal Assay Using Human Complement (hSBA) Titer From Baseline for Each MenACWY Strains: 1 Month After Vaccination 2 in Group 1 Compared to 1 Month After Vaccination 1 in Group 2

    4-fold increase was defined as: 1) for participants with baseline hSBA titer below limit of detection (LOD) (or hSBA titer less than \[\<\] 1:4), 4-fold rise was defined as hSBA titer greater than or equal to (\>=) 1:16; 2) baseline hSBA titer \>=LOD and \< lower limit of quantitation (LLOQ) (i.e. hSBA titer of 1:8), 4-fold rise was defined as hSBA titer \>=4 times LLOQ; 3) baseline hSBA titer \>=LLOQ, 4-fold rise was defined as hSBA titer \>=4 times baseline titer. Exact 2-sided confidence interval (CI) using Clopper and Pearson method was presented. Analysis was performed on post-vaccination (PV) 1 evaluable immunogenicity population (EIP) for Group 2 and PV2 evaluable immunogenicity population for Group 1. Here, 'Overall Number of Participants Analyzed' represented as 'N' and 'Number Analyzed' represented as 'n'.

    Time frame: Baseline (pre-vaccination on Day 1), 1 month after Vaccination 2 in Group 1 and 1 month after Vaccination 1 in Group 2

  2. Percentage of Participants Achieving At Least 4-Fold Rise in hSBA Titer From Baseline for Each of the MenACWY Strains: 1 Month After Vaccination 2 in Group 3 Compared to 1 Month After Vaccination 1 in Group 4

    4-fold increase was defined as: 1) for participants with baseline hSBA titer below LOD (or hSBA titer \<1:4), 4-fold rise was defined as hSBA titer \>=1:16; 2) baseline hSBA titer \>=LOD (i.e., hSBA titer of \>=1:4) and \< LLOQ (i.e., hSBA titer of 1:8), 4-fold rise was defined as hSBA titer \>=4times LLOQ; 3) baseline hSBA titer \>=LLOQ, 4-fold rise was defined as hSBA titer \>=4 times baseline titer. Exact 2-sided CI using Clopper and Pearson method was presented. Here, 'Overall Number of Participants Analyzed' represented as 'N' and 'Number Analyzed' represented as 'n'.

    Time frame: Baseline (pre-vaccination on Day 1), 1 month after Vaccination 2 in Group 3 and 1 month after Vaccination 1 in Group 4

  3. Percentage of Participants Achieving hSBA Titer Greater Than or Equal to (>=) LLOQ for All Primary Neisseria Meningitidis Group B (MenB) Test Strains Combined (Composite Response): Groups 1 and 3 Combined Versus Groups 2 and 4 Combined

    Percentage of participants achieving hSBA titer \>= LLOQ (1:16 for strain A22 and 1:8 for strains A56, B24, and B44) for all MenB test strains (A22, A56, B24 and B44) combined were reported in this outcome measure. Exact 2-sided CI using the Clopper and Pearson method was presented.

    Time frame: 1 month after Vaccination 2

  4. Percentage of Participants Achieving At Least a 4-Fold Rise in hSBA Titer From Baseline For Each Primary MenB Test Strains at 1 Month After Vaccination 2: Groups 1 and 3 Combined Versus Groups 2 and 4 Combined

    Percentage of participants achieving at least a 4-fold rise in hSBA titer for each primary MenB test strains (A22, A56, B24 and B44) were reported in this outcome measure. Exact 2-sided CI using the Clopper and Pearson method was presented.

    Time frame: Baseline (pre-vaccination on Day 1), 1 month after Vaccination 2

  5. Percentage of Participants With Local Reactions Within 7 Days After Vaccination 1: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)

    Local reactions included pain at injection site, redness and swelling and were recorded by participants in an electronic diary (e-diary). Redness and swelling were measured and recorded in caliper units. 1 caliper unit =0.5 centimeter (cm) and graded as mild: \>2.0 to 5.0 cm, moderate: \>5.0 to 10.0 cm and severe: \>10.0 cm. Pain at injection site was graded as mild: did not interfere with daily activity, moderate: interfered with daily activity and severe: prevented daily activity. Percentage of participants with local reactions at injection site were reported in this outcome measure. Exact 2-sided CI was based on the Clopper and Pearson method.

    Time frame: Within 7 days after Vaccination 1

  6. Percentage of Participants With Local Reactions Within 7 Days After Vaccination 2: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)

    Local reactions included pain at injection site, redness and swelling and were recorded by participants in an e-diary. Redness and swelling were measured and recorded in caliper units. 1 caliper unit =0.5 cm and graded as mild: \>2.0 to 5.0 cm, moderate: \>5.0 to 10.0 cm and severe: \>10.0 cm. Pain at injection site was graded as mild: did not interfere with daily activity, moderate: interfered with daily activity and severe: prevented daily activity. Percentage of participants with local reactions at injection site were reported in this outcome measure. Exact 2-sided CI was based on the Clopper and Pearson method.

    Time frame: Within 7 days after Vaccination 2

  7. Percentage of Participants With Systemic Events Within 7 Days After Vaccination 1: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)

    Systemic events were recorded by participants in e-diary. Fever was defined as temperature \>=38.0 degrees (deg) Celsius (C) and was categorized as 38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, muscle pain and joint pain were graded as mild: did not interfere with activity, moderate: some interference with activity and severe: prevented daily routine activity. Vomiting was graded as mild: 1 to 2 times in 24 hours(h), moderate: \>2 times in 24h and severe: required intravenous hydration. Diarrhea was graded as mild: 2 to 3 loose stools in 24h, moderate: 4 to 5 loose stools in 24h and severe: 6 or more loose stools in 24h. Exact 2-sided CI was based on the Clopper and Pearson method.

    Time frame: Within 7 days after Vaccination 1

  8. Percentage of Participants With Systemic Events Within 7 Days After Vaccination 2: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)

    Systemic events were recorded by participants in e-diary. Fever was defined as temperature \>=38.0 deg C and was categorized as 38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, muscle pain and joint pain were graded as mild: did not interfere with activity, moderate: some interference with activity and severe: prevented daily routine activity. Vomiting was graded as mild: 1 to 2 times in 24h, moderate: \>2 times in 24h and severe: required intravenous hydration. Diarrhea was graded as mild: 2 to 3 loose stools in 24h, moderate: 4 to 5 loose stools in 24h and severe: 6 or more loose stools in 24h. Exact 2-sided CI was based on the Clopper and Pearson method.

    Time frame: Within 7 days after Vaccination 2

  9. Percentage of Participants With Use of Antipyretic Medication Within 7 Days After Vaccination 1: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)

    The use of antipyretic medication was recorded by participants in an e-diary for 7 days after vaccination. Exact 2-sided CI was based on the Clopper and Pearson method.

    Time frame: Within 7 days after Vaccination 1

  10. Percentage of Participants With Use of Antipyretic Medication Within 7 Days After Vaccination 2: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)

    The use of antipyretic medication recorded by participants in an e-diary for 7 days after vaccination. Exact 2-sided CI was based on the Clopper and Pearson method.

    Time frame: Within 7 days after Vaccination 2

  11. Percentage of Participants With Adverse Events (AEs) Within 30 Days After Vaccination 1: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)

    An AE was any untoward medical occurrence in a participant, temporally associated with the use of investigational product, whether or not considered related to the investigational product. Exact 2-sided CI was based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.

    Time frame: Within 30 days after Vaccination 1

  12. Percentage of Participants With AEs Within 30 Days After Vaccination 2: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)

    An AE was any untoward medical occurrence in a participant, temporally associated with the use of investigational product, whether or not considered related to the investigational product. Exact 2-sided CI was based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.

    Time frame: Within 30 days after Vaccination 2

  13. Percentage of Participants With AEs Within 30 Days After Any Vaccination: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)

    An AE was any untoward medical occurrence in a participant, temporally associated with the use of investigational product, whether or not considered related to the investigational product. Exact 2-sided CI was based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.

    Time frame: Within 30 days after any vaccination

  14. Percentage of Participants With AEs During Vaccination Phase: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)

    An AE was any untoward medical occurrence in a participant, temporally associated with the use of investigational product, whether or not considered related to the investigational product. Exact 2-sided CI was based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.

    Time frame: From day of Vaccination 1 (Day 1) up to 1 month after Vaccination 2 (approximately 7 months)

  15. Percentage of Participants With Serious Adverse Events (SAEs) Within 30 Days After Vaccination 1: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)

    An SAE was any untoward medical occurrence that, at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent disability/incapacity; congenital anomaly/birth defect and other important medical events. Exact 2-sided CI was based on the Clopper and Pearson method.

    Time frame: Within 30 days after Vaccination 1

  16. Percentage of Participants With SAEs Within 30 Days After Vaccination 2: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)

    An SAE was any untoward medical occurrence that, at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent disability/incapacity; congenital anomaly/birth defect and other important medical events. Exact 2-sided CI was based on the Clopper and Pearson method.

    Time frame: Within 30 days after Vaccination 2

  17. Percentage of Participants With SAEs Within 30 Days After Any Vaccination: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)

    An SAE was any untoward medical occurrence that, at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent disability/ incapacity; congenital anomaly/birth defect and other important medical events. Exact 2-sided CI was based on the Clopper and Pearson method.

    Time frame: Within 30 days after any vaccination

  18. Percentage of Participants With SAEs During Vaccination Phase: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)

    An SAE was any untoward medical occurrence that, at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent disability/ incapacity; congenital anomaly/birth defect and other important medical events. Exact 2-sided CI was based on the Clopper and Pearson method.

    Time frame: From day of Vaccination 1 (Day 1) up to 1 month after Vaccination 2 (approximately 7 months)

  19. Percentage of Participants With SAEs During Follow-up Phase: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)

    An SAE was any untoward medical occurrence that, at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent disability/ incapacity; congenital anomaly/birth defect and other important medical events. Exact 2-sided CI was based on the Clopper and Pearson method.

    Time frame: From 1 month after Vaccination 2 up to 6 months after Vaccination 2 (approximately 5 months)

  20. Percentage of Participants With SAEs Throughout the Study: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)

    An SAE was any untoward medical occurrence that, at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent disability/ incapacity; congenital anomaly/birth defect and other important medical events. Exact 2-sided CI was based on the Clopper and Pearson method.

    Time frame: From day of Vaccination 1 (Day 1) up to 6 months after Vaccination 2 (approximately 12 months)

  21. Percentage of Participants With Medically Attended Adverse Events (MAEs) Within 30 Days After Vaccination 1: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)

    MAE was defined as a non-serious AE that resulted in an evaluation at a medical facility. Exact 2-sided CI was based on the Clopper and Pearson method.

    Time frame: Within 30 days after Vaccination 1

  22. Percentage of Participants With MAEs Within 30 Days After Vaccination 2: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)

    MAE was defined as a non-serious AE that resulted in an evaluation at a medical facility. Exact 2-sided CI was based on the Clopper and Pearson method.

    Time frame: Within 30 days after Vaccination 2

  23. Percentage of Participants With MAEs Within 30 Days After Any Vaccination: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)

    MAE was defined as a non-serious AE that resulted in an evaluation at a medical facility. Exact 2-sided CI was based on the Clopper and Pearson method.

    Time frame: Within 30 days after any vaccination

  24. Percentage of Participants With MAEs During Vaccination Phase: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)

    MAE was defined as a non-serious AE that resulted in an evaluation at a medical facility. Exact 2-sided CI was based on the Clopper and Pearson method.

    Time frame: From day of Vaccination 1 (Day 1) up to 1 month after Vaccination 2 (approximately 7 months)

  25. Percentage of Participants With MAEs During Follow-up Phase: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)

    MAE was defined as a non-serious AE that resulted in an evaluation at a medical facility. Exact 2-sided CI was based on the Clopper and Pearson method.

    Time frame: From 1 month after Vaccination 2 up to 6 months after Vaccination 2 (approximately 5 months)

  26. Percentage of Participants With MAEs Throughout the Study: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)

    MAE was defined as a non-serious AE that resulted in an evaluation at a medical facility. Exact 2-sided CI was based on the Clopper and Pearson method.

    Time frame: From day of Vaccination 1 (Day 1) up to 6 months after Vaccination 2 (approximately 12 months)

  27. Percentage of Participants With Newly Diagnosed Chronic Medical Condition (NDCMC) Within 30 Days After Vaccination 1: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)

    An NDCMC was defined as a disease or medical condition, not previously identified, that is expected to be persistent or otherwise long-lasting in its effects. Exact 2-sided CI was based on the Clopper and Pearson method.

    Time frame: Within 30 days after Vaccination 1

  28. Percentage of Participants With NDCMC Within 30 Days After Vaccination 2: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)

    An NDCMC was defined as a disease or medical condition, not previously identified, that is expected to be persistent or otherwise long-lasting in its effects. Exact 2-sided CI was based on the Clopper and Pearson method.

    Time frame: Within 30 days after Vaccination 2

  29. Percentage of Participants With NDCMC Within 30 Days After Any Vaccination: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)

    An NDCMC was defined as a disease or medical condition, not previously identified, that is expected to be persistent or otherwise long-lasting in its effects. Exact 2-sided CI was based on the Clopper and Pearson method.

    Time frame: Within 30 Days after any vaccination

  30. Percentage of Participants With NDCMC During Vaccination Phase: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)

    An NDCMC was defined as a disease or medical condition, not previously identified, that is expected to be persistent or otherwise long-lasting in its effects. Exact 2-sided CI was based on the Clopper and Pearson method.

    Time frame: From day of Vaccination 1 (Day 1) up to 1 month after Vaccination 2 (approximately 7 months)

  31. Percentage of Participants With NDCMC During Follow-up Phase: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)

    An NDCMC was defined as a disease or medical condition, not previously identified, that is expected to be persistent or otherwise long-lasting in its effects. Exact 2-sided CI was based on the Clopper and Pearson method.

    Time frame: From 1 month after Vaccination 2 up to 6 months after Vaccination 2 (approximately 5 months)

  32. Percentage of Participants With NDCMC Throughout the Study: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)

    An NDCMC was defined as a disease or medical condition, not previously identified, that is expected to be persistent or otherwise long-lasting in its effects. Exact 2-sided CI was based on the Clopper and Pearson method.

    Time frame: From day of Vaccination 1 (Day 1) up to 6 months after Vaccination 2 (approximately 12 months)

  33. Percentage of Participants With Immediate AE Within 30 Minutes After Vaccination 1: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)

    Immediate AEs were defined as AEs occurring within the first 30 minutes after investigational product administration. Exact 2-sided CI was based on the Clopper and Pearson method.

    Time frame: Within 30 minutes after Vaccination 1

  34. Percentage of Participants With Immediate AE Within 30 Minutes After Vaccination 2: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)

    Immediate AEs were defined as AEs occurring within the first 30 minutes after investigational product administration. Exact 2-sided CI was based on the Clopper and Pearson method.

    Time frame: Within 30 minutes after Vaccination 2

  35. Percentage of Participants Who Missed Days of School or Work Due to AEs During Vaccination Phase: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)

    An AE was any untoward medical occurrence in a participant, temporally associated with the use of investigational product, whether or not considered related to the investigational product. Percentage of participants who missed days of school or work due to AEs during vaccination phase were reported in this outcome measure.

    Time frame: From day of Vaccination 1 (Day 1) up to 1 month after Vaccination 2 (approximately 7 months)

Secondary outcomes

  1. Percentage of Participants Achieving At Least 4-Fold Rise in hSBA Titer From Baseline for Each MenACWY Test Strains: 1 Month After Vaccination 1 in Group 1 Compared to Group 2

    4-fold increase was defined as: 1) for participants with baseline hSBA titer below LOD (or hSBA titer \<1:4), 4-fold rise was defined as hSBA titer \>=1:16; 2) baseline hSBA titer \>=LOD (i.e., hSBA titer of \>=1:4) and \< LLOQ (i.e. hSBA titer of 1:8), 4-fold rise was defined as hSBA titer \>=4times LLOQ; 3) baseline hSBA titer \>=LLOQ, 4-fold rise was defined as hSBA titer \>=4 times baseline titer. Exact 2-sided CI using Clopper and Pearson method was presented.

    Time frame: Baseline (pre-vaccination on Day 1), 1 month after Vaccination 1

  2. Percentage of Participants Achieving At Least 4-Fold Rise in hSBA Titer From Baseline for Each MenACWY Test Strains: 1 Month After Vaccination 1 in Group 3 Compared to Group 4

    4-fold increase was defined as: 1) for participants with baseline hSBA titer below LOD (or hSBA titer \<1:4), 4-fold rise was defined as hSBA titer \>=1:16; 2) baseline hSBA titer \>=LOD (i.e., hSBA titer of \>=1:4) and \< LLOQ (i.e. hSBA titer of 1:8), 4-fold rise was defined as hSBA titer \>=4 times LLOQ; 3) baseline hSBA titer \> =LLOQ, 4-fold rise was defined as hSBA titer \>=4 times baseline titer. Exact 2-sided CI using Clopper and Pearson method was presented.

    Time frame: Baseline (pre-vaccination on Day 1), 1 month after Vaccination 1

07

Results

Posted Apr 18, 2023

Participant flow

Vaccination Phase (Approx. 7 Months)
Participant flow — Vaccination Phase (Approx. 7 Months)
MilestoneACWY-Naive: Group 1 MenABCWY + Saline (Immunogenicity and Safety Set)ACWY-Naive: Group 2 Trumenba+ MenACWY - CRM (Immunogenicity and Safety Set)ACWY-Experienced: Group 3 MenABCWY + Saline (Immunogenicity and Safety Set)ACWY-Experienced: Group 4 Trumenba+ MenACWY - CRM (Immunogenicity and Safety Set)ACWY-Naive: Group 5 MenABCWY + Saline (Safety Set)ACWY-Naive: Group 6 Trumenba+ MenACWY - CRM (Safety Set)ACWY-Experienced: Group 7 MenABCWY + Saline (Safety Set)ACWY-Experienced: Group 8 Trumenba+ MenACWY - CRM (Safety Set)
Started5522765282615445715459
Vaccination 15472745262615375615359
Vaccination 25002544532184814612345
Completed4902484402094764512244
Not completed6228885268123215
Withdrew: Lost to follow-up26154222303185
Withdrew: Medication error without associated adverse event00011000
Withdrew: No longer met eligibility criteria51523023
Withdrew: Pregnancy10201000
Withdrew: Protocol violation10530030
Withdrew: Other00320101
Withdrew: Adverse event31010000
Withdrew: Withdrawal by subject115181410354
Withdrew: Withdrawal by parent/guardian10411716432
Withdrew: Withdrawn before vaccination52207110
Follow-up Phase (Approx. 5 Months)
Participant flow — Follow-up Phase (Approx. 5 Months)
MilestoneACWY-Naive: Group 1 MenABCWY + Saline (Immunogenicity and Safety Set)ACWY-Naive: Group 2 Trumenba+ MenACWY - CRM (Immunogenicity and Safety Set)ACWY-Experienced: Group 3 MenABCWY + Saline (Immunogenicity and Safety Set)ACWY-Experienced: Group 4 Trumenba+ MenACWY - CRM (Immunogenicity and Safety Set)ACWY-Naive: Group 5 MenABCWY + Saline (Safety Set)ACWY-Naive: Group 6 Trumenba+ MenACWY - CRM (Safety Set)ACWY-Experienced: Group 7 MenABCWY + Saline (Safety Set)ACWY-Experienced: Group 8 Trumenba+ MenACWY - CRM (Safety Set)
Started4902484402094764512244
Completed4872434402084754512043
Not completed35011021
Withdrew: Lost to follow-up35001021
Withdrew: Protocol violation00010000

Outcome measures

PrimaryPercentage of Participants Achieving At Least 4-Fold Rise in Serum Bactericidal Assay Using Human Complement (hSBA) Titer From Baseline for Each MenACWY Strains: 1 Month After Vaccination 2 in Group 1 Compared to 1 Month After Vaccination 1 in Group 2

4-fold increase was defined as: 1) for participants with baseline hSBA titer below limit of detection (LOD) (or hSBA titer less than \[\<\] 1:4), 4-fold rise was defined as hSBA titer greater than or equal to (\>=) 1:16; 2) baseline hSBA titer \>=LOD and \< lower limit of quantitation (LLOQ) (i.e. hSBA titer of 1:8), 4-fold rise was defined as hSBA titer \>=4 times LLOQ; 3) baseline hSBA titer \>=LLOQ, 4-fold rise was defined as hSBA titer \>=4 times baseline titer. Exact 2-sided confidence interval (CI) using Clopper and Pearson method was presented. Analysis was performed on post-vaccination (PV) 1 evaluable immunogenicity population (EIP) for Group 2 and PV2 evaluable immunogenicity population for Group 1. Here, 'Overall Number of Participants Analyzed' represented as 'N' and 'Number Analyzed' represented as 'n'.

Time frame:
Baseline (pre-vaccination on Day 1), 1 month after Vaccination 2 in Group 1 and 1 month after Vaccination 1 in Group 2
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving At Least 4-Fold Rise in Serum Bactericidal Assay Using Human Complement (hSBA) Titer From Baseline for Each MenACWY Strains: 1 Month After Vaccination 2 in Group 1 Compared to 1 Month After Vaccination 1 in Group 2
Percentage of participantsACWY-Naive: Group 1 MenABCWY + Saline (Immunogenicity and Safety Set)ACWY-Naive: Group 2 Trumenba+ MenACWY - CRM (Immunogenicity and Safety Set)
MenA97.8 (95.9 to 98.9)95.3 (91.9 to 97.5)
MenC93.3 (90.6 to 95.5)52.4 (46.0 to 58.7)
MenW97.3 (95.3 to 98.6)73.0 (66.9 to 78.4)
MenY94.4 (91.8 to 96.3)70.6 (64.5 to 76.2)
Statistical analysis
  • ACWY-Naive: Group 1 MenABCWY + Saline (Immunogenicity and Safety Set) vs ACWY-Naive: Group 2 Trumenba+ MenACWY - CRM (Immunogenicity and Safety Set) · Based on Miettinen and Nurminen method. · Difference in percentage of participants: 2.5 · 95% CI -0.2 to 6.0
  • ACWY-Naive: Group 1 MenABCWY + Saline (Immunogenicity and Safety Set) vs ACWY-Naive: Group 2 Trumenba+ MenACWY - CRM (Immunogenicity and Safety Set) · Difference in percentage of participants: 41.0 · 95% CI 34.4 to 47.5
  • ACWY-Naive: Group 1 MenABCWY + Saline (Immunogenicity and Safety Set) vs ACWY-Naive: Group 2 Trumenba+ MenACWY - CRM (Immunogenicity and Safety Set) · Difference in percentage of participants: 24.3 · 95% CI 18.8 to 30.4
  • ACWY-Naive: Group 1 MenABCWY + Saline (Immunogenicity and Safety Set) vs ACWY-Naive: Group 2 Trumenba+ MenACWY - CRM (Immunogenicity and Safety Set) · Difference in percentage of participants: 23.8 · 95% CI 18.0 to 30.1
PrimaryPercentage of Participants Achieving At Least 4-Fold Rise in hSBA Titer From Baseline for Each of the MenACWY Strains: 1 Month After Vaccination 2 in Group 3 Compared to 1 Month After Vaccination 1 in Group 4

4-fold increase was defined as: 1) for participants with baseline hSBA titer below LOD (or hSBA titer \<1:4), 4-fold rise was defined as hSBA titer \>=1:16; 2) baseline hSBA titer \>=LOD (i.e., hSBA titer of \>=1:4) and \< LLOQ (i.e., hSBA titer of 1:8), 4-fold rise was defined as hSBA titer \>=4times LLOQ; 3) baseline hSBA titer \>=LLOQ, 4-fold rise was defined as hSBA titer \>=4 times baseline titer. Exact 2-sided CI using Clopper and Pearson method was presented. Here, 'Overall Number of Participants Analyzed' represented as 'N' and 'Number Analyzed' represented as 'n'.

Time frame:
Baseline (pre-vaccination on Day 1), 1 month after Vaccination 2 in Group 3 and 1 month after Vaccination 1 in Group 4
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving At Least 4-Fold Rise in hSBA Titer From Baseline for Each of the MenACWY Strains: 1 Month After Vaccination 2 in Group 3 Compared to 1 Month After Vaccination 1 in Group 4
Percentage of participantsACWY-Experienced: Group 3 MenABCWY + Saline (Immunogenicity and Safety Set)ACWY-Experienced: Group 4 Trumenba+ MenACWY - CRM (Immunogenicity and Safety Set)
MenA93.8 (90.9 to 96.0)96.9 (93.7 to 98.8)
MenC93.8 (90.9 to 96.0)94.7 (90.9 to 97.2)
MenW97.1 (94.8 to 98.5)96.4 (93.0 to 98.4)
MenY93.0 (90.0 to 95.4)93.7 (89.7 to 96.5)
Statistical analysis
  • ACWY-Experienced: Group 3 MenABCWY + Saline (Immunogenicity and Safety Set) vs ACWY-Experienced: Group 4 Trumenba+ MenACWY - CRM (Immunogenicity and Safety Set) · Difference in percentage of participants: -3.2 · 95% CI -6.5 to 0.5
  • ACWY-Experienced: Group 3 MenABCWY + Saline (Immunogenicity and Safety Set) vs ACWY-Experienced: Group 4 Trumenba+ MenACWY - CRM (Immunogenicity and Safety Set) · Difference in percentage of participants: -0.9 · 95% CI -4.6 to 3.3
  • ACWY-Experienced: Group 3 MenABCWY + Saline (Immunogenicity and Safety Set) vs ACWY-Experienced: Group 4 Trumenba+ MenACWY - CRM (Immunogenicity and Safety Set) · Difference in percentage of participants: 0.7 · 95% CI -2.2 to 4.3
  • ACWY-Experienced: Group 3 MenABCWY + Saline (Immunogenicity and Safety Set) vs ACWY-Experienced: Group 4 Trumenba+ MenACWY - CRM (Immunogenicity and Safety Set) · Difference in percentage of participants: -0.7 · 95% CI -4.6 to 3.8
PrimaryPercentage of Participants Achieving hSBA Titer Greater Than or Equal to (>=) LLOQ for All Primary Neisseria Meningitidis Group B (MenB) Test Strains Combined (Composite Response): Groups 1 and 3 Combined Versus Groups 2 and 4 Combined

Percentage of participants achieving hSBA titer \>= LLOQ (1:16 for strain A22 and 1:8 for strains A56, B24, and B44) for all MenB test strains (A22, A56, B24 and B44) combined were reported in this outcome measure. Exact 2-sided CI using the Clopper and Pearson method was presented.

Time frame:
1 month after Vaccination 2
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving hSBA Titer Greater Than or Equal to (>=) LLOQ for All Primary Neisseria Meningitidis Group B (MenB) Test Strains Combined (Composite Response): Groups 1 and 3 Combined Versus Groups 2 and 4 Combined
Percentage of participantsGroups 1+3 Combined MenABCWY + Saline (Immunogenicity and Safety Set)Groups 2+4 Combined Trumenba + MenACWY-CRM (Immunogenicity and Safety Set)
Percentage of Participants Achieving hSBA Titer Greater Than or Equal to (>=) LLOQ for All Primary Neisseria Meningitidis Group B (MenB) Test Strains Combined (Composite Response): Groups 1 and 3 Combined Versus Groups 2 and 4 Combined78.3 (75.2 to 81.2)68.7 (63.8 to 73.3)
Statistical analysis
  • Groups 1+3 Combined MenABCWY + Saline (Immunogenicity and Safety Set) vs Groups 2+4 Combined Trumenba + MenACWY-CRM (Immunogenicity and Safety Set) · Difference in percentage of participants: 9.6 · 95% CI 4.2 to 15.2
PrimaryPercentage of Participants Achieving At Least a 4-Fold Rise in hSBA Titer From Baseline For Each Primary MenB Test Strains at 1 Month After Vaccination 2: Groups 1 and 3 Combined Versus Groups 2 and 4 Combined

Percentage of participants achieving at least a 4-fold rise in hSBA titer for each primary MenB test strains (A22, A56, B24 and B44) were reported in this outcome measure. Exact 2-sided CI using the Clopper and Pearson method was presented.

Time frame:
Baseline (pre-vaccination on Day 1), 1 month after Vaccination 2
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving At Least a 4-Fold Rise in hSBA Titer From Baseline For Each Primary MenB Test Strains at 1 Month After Vaccination 2: Groups 1 and 3 Combined Versus Groups 2 and 4 Combined
Percentage of participantsGroups 1+3 Combined MenABCWY + Saline (Immunogenicity and Safety Set)Groups 2+4 Combined Trumenba + MenACWY-CRM (Immunogenicity and Safety Set)
A2283.0 (80.2 to 85.6)79.0 (74.7 to 82.9)
A5695.9 (94.3 to 97.2)94.5 (91.8 to 96.5)
B2468.1 (64.8 to 71.2)57.2 (52.3 to 62.0)
B4486.5 (84.0 to 88.7)79.2 (75.0 to 83.0)
Statistical analysis
  • Groups 1+3 Combined MenABCWY + Saline (Immunogenicity and Safety Set) vs Groups 2+4 Combined Trumenba + MenACWY-CRM (Immunogenicity and Safety Set) · Difference in percentage of participants: 4.0 · 95% CI -0.7 to 8.9
  • Groups 1+3 Combined MenABCWY + Saline (Immunogenicity and Safety Set) vs Groups 2+4 Combined Trumenba + MenACWY-CRM (Immunogenicity and Safety Set) · Difference in percentage of participants: 1.4 · 95% CI -1.0 to 4.3
  • Groups 1+3 Combined MenABCWY + Saline (Immunogenicity and Safety Set) vs Groups 2+4 Combined Trumenba + MenACWY-CRM (Immunogenicity and Safety Set) · Difference in percentage of participants: 10.9 · 95% CI 5.2 to 16.6
  • Groups 1+3 Combined MenABCWY + Saline (Immunogenicity and Safety Set) vs Groups 2+4 Combined Trumenba + MenACWY-CRM (Immunogenicity and Safety Set) · Difference in percentage: 7.3 · 95% CI 2.9 to 11.9
PrimaryPercentage of Participants With Local Reactions Within 7 Days After Vaccination 1: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)

Local reactions included pain at injection site, redness and swelling and were recorded by participants in an electronic diary (e-diary). Redness and swelling were measured and recorded in caliper units. 1 caliper unit =0.5 centimeter (cm) and graded as mild: \>2.0 to 5.0 cm, moderate: \>5.0 to 10.0 cm and severe: \>10.0 cm. Pain at injection site was graded as mild: did not interfere with daily activity, moderate: interfered with daily activity and severe: prevented daily activity. Percentage of participants with local reactions at injection site were reported in this outcome measure. Exact 2-sided CI was based on the Clopper and Pearson method.

Time frame:
Within 7 days after Vaccination 1
Reported as:
Number · Percentage of participants
Percentage of Participants With Local Reactions Within 7 Days After Vaccination 1: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)
Percentage of participantsGroups 1+3+5+7 Combined MenABCWY + SalineGroups 2+4+6+8 Combined Trumenba + MenACWY-CRM
Redness: Mild8.8 (7.5 to 10.3)7.3 (5.4 to 9.6)
Redness: Moderate14.5 (12.8 to 16.2)10.0 (7.8 to 12.6)
Redness: Severe2.5 (1.8 to 3.3)2.2 (1.2 to 3.7)
Swelling: Mild10.5 (9.0 to 12.0)8.3 (6.2 to 10.7)
Swelling: Moderate13.3 (11.7 to 15.0)12.4 (9.9 to 15.2)
Swelling: Severe1.2 (0.7 to 1.8)0.8 (0.3 to 1.8)
Pain at injection site: Mild32.3 (30.1 to 34.6)31.1 (27.5 to 34.9)
Pain at injection site: Moderate49.5 (47.1 to 51.9)47.6 (43.7 to 51.6)
Pain at injection site: Severe7.5 (6.3 to 8.8)6.3 (4.6 to 8.5)
PrimaryPercentage of Participants With Local Reactions Within 7 Days After Vaccination 2: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)

Local reactions included pain at injection site, redness and swelling and were recorded by participants in an e-diary. Redness and swelling were measured and recorded in caliper units. 1 caliper unit =0.5 cm and graded as mild: \>2.0 to 5.0 cm, moderate: \>5.0 to 10.0 cm and severe: \>10.0 cm. Pain at injection site was graded as mild: did not interfere with daily activity, moderate: interfered with daily activity and severe: prevented daily activity. Percentage of participants with local reactions at injection site were reported in this outcome measure. Exact 2-sided CI was based on the Clopper and Pearson method.

Time frame:
Within 7 days after Vaccination 2
Reported as:
Number · Percentage of participants
Percentage of Participants With Local Reactions Within 7 Days After Vaccination 2: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)
Percentage of participantsGroups 1+3+5+7 Combined MenABCWY + SalineGroups 2+4+6+8 Combined Trumenba + MenACWY-CRM
Redness: Mild7.7 (6.4 to 9.2)6.6 (4.7 to 9.1)
Redness: Moderate12.6 (10.9 to 14.4)7.2 (5.1 to 9.7)
Redness: Severe3.0 (2.1 to 4.0)0.9 (0.3 to 2.2)
Swelling: Mild10.4 (8.9 to 12.1)6.4 (4.5 to 8.9)
Swelling: Moderate12.8 (11.1 to 14.6)8.1 (5.9 to 10.8)
Swelling: Severe1.0 (0.5 to 1.6)0.2 (0.0 to 1.0)
Pain at injection site: Mild29.1 (26.7 to 31.5)33.1 (29.1 to 37.3)
Pain at injection site: Moderate48.8 (46.2 to 51.4)40.3 (36.1 to 44.6)
Pain at injection site: Severe6.5 (5.3 to 7.9)5.3 (3.5 to 7.6)
PrimaryPercentage of Participants With Systemic Events Within 7 Days After Vaccination 1: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)

Systemic events were recorded by participants in e-diary. Fever was defined as temperature \>=38.0 degrees (deg) Celsius (C) and was categorized as 38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, muscle pain and joint pain were graded as mild: did not interfere with activity, moderate: some interference with activity and severe: prevented daily routine activity. Vomiting was graded as mild: 1 to 2 times in 24 hours(h), moderate: \>2 times in 24h and severe: required intravenous hydration. Diarrhea was graded as mild: 2 to 3 loose stools in 24h, moderate: 4 to 5 loose stools in 24h and severe: 6 or more loose stools in 24h. Exact 2-sided CI was based on the Clopper and Pearson method.

Time frame:
Within 7 days after Vaccination 1
Reported as:
Number · Percentage of participants
Percentage of Participants With Systemic Events Within 7 Days After Vaccination 1: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)
Percentage of participantsGroups 1+3+5+7 Combined MenABCWY + SalineGroups 2+4+6+8 Combined Trumenba + MenACWY-CRM
Fever: 38.0 deg C to 38.4 deg C3.7 (2.8 to 4.7)2.0 (1.1 to 3.5)
Fever: >38.4 deg C to 38.9 deg C1.6 (1.0 to 2.3)2.8 (1.7 to 4.4)
Fever: >38.9 deg C to 40.0 deg C0.6 (0.3 to 1.1)0.9 (0.3 to 2.0)
Fever: >40.0 deg C0.0 (0.0 to 0.2)0.0 (0.0 to 0.6)
Fatigue: Mild23.5 (21.5 to 25.5)25.7 (22.4 to 29.3)
Fatigue: Moderate25.5 (23.4 to 27.6)25.7 (22.4 to 29.3)
Fatigue: Severe3.2 (2.4 to 4.1)3.3 (2.0 to 5.0)
Headache: Mild25.6 (23.6 to 27.8)24.5 (21.2 to 28.0)
Headache: Moderate19.2 (17.4 to 21.1)20.4 (17.3 to 23.7)
Headache: Severe1.9 (1.3 to 2.7)2.0 (1.1 to 3.5)
Chills: Mild12.6 (11.1 to 14.2)10.2 (8.0 to 12.8)
Chills: Moderate6.7 (5.5 to 7.9)7.8 (5.9 to 10.2)
Chills: Severe0.8 (0.4 to 1.3)1.6 (0.8 to 2.9)
Vomiting: Mild2.5 (1.8 to 3.4)2.0 (1.1 to 3.5)
Vomiting: Moderate0.6 (0.3 to 1.1)0.9 (0.3 to 2.0)
Vomiting: Severe0.0 (0.0 to 0.2)0.0 (0.0 to 0.6)
Diarrhea: Mild8.7 (7.5 to 10.2)11.9 (9.5 to 14.7)
Diarrhea: Moderate2.0 (1.4 to 2.7)1.6 (0.8 to 2.9)
Diarrhea: Severe0.3 (0.1 to 0.7)0.0 (0.0 to 0.6)
Muscle Pain: Mild13.6 (12.0 to 15.3)13.5 (10.9 to 16.4)
Muscle Pain: Moderate10.5 (9.1 to 12.1)11.9 (9.5 to 14.7)
Muscle Pain: Severe1.6 (1.1 to 2.3)2.0 (1.1 to 3.5)
Joint Pain: Mild10.7 (9.3 to 12.2)12.9 (10.4 to 15.7)
Joint Pain: Moderate8.6 (7.3 to 10.0)8.6 (6.6 to 11.1)
Joint Pain: Severe1.0 (0.6 to 1.6)1.1 (0.4 to 2.2)
PrimaryPercentage of Participants With Systemic Events Within 7 Days After Vaccination 2: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)

Systemic events were recorded by participants in e-diary. Fever was defined as temperature \>=38.0 deg C and was categorized as 38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, muscle pain and joint pain were graded as mild: did not interfere with activity, moderate: some interference with activity and severe: prevented daily routine activity. Vomiting was graded as mild: 1 to 2 times in 24h, moderate: \>2 times in 24h and severe: required intravenous hydration. Diarrhea was graded as mild: 2 to 3 loose stools in 24h, moderate: 4 to 5 loose stools in 24h and severe: 6 or more loose stools in 24h. Exact 2-sided CI was based on the Clopper and Pearson method.

Time frame:
Within 7 days after Vaccination 2
Reported as:
Number · Percentage of participants
Percentage of Participants With Systemic Events Within 7 Days After Vaccination 2: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)
Percentage of participantsGroups 1+3+5+7 Combined MenABCWY + SalineGroups 2+4+6+8 Combined Trumenba + MenACWY-CRM
Fever: 38.0 deg C to 38.4 deg C1.8 (1.2 to 2.6)0.4 (0.0 to 1.4)
Fever: >38.4 deg C to 38.9 deg C0.3 (0.1 to 0.7)0.9 (0.3 to 2.2)
Fever: >38.9 deg C to 40.0 deg C0.2 (0.0 to 0.6)0.2 (0.0 to 1.0)
Fever: >40.0 deg C0.0 (0.0 to 0.3)0.0 (0.0 to 0.7)
Fatigue: Mild22.8 (20.7 to 25.1)22.0 (18.5 to 25.8)
Fatigue: Moderate21.8 (19.7 to 24.0)19.9 (16.6 to 23.6)
Fatigue: Severe2.9 (2.1 to 3.9)1.7 (0.8 to 3.2)
Headache: Mild21.3 (19.2 to 23.5)21.1 (17.7 to 24.8)
Headache: Moderate16.8 (14.9 to 18.8)16.2 (13.1 to 19.6)
Headache: Severe1.7 (1.1 to 2.5)0.6 (0.1 to 1.6)
Chills: Mild9.9 (8.5 to 11.6)8.8 (6.6 to 11.6)
Chills: Moderate6.0 (4.9 to 7.4)5.8 (4.0 to 8.2)
Chills: Severe0.4 (0.2 to 0.9)1.5 (0.7 to 2.9)
Vomiting: Mild1.4 (0.8 to 2.1)0.8 (0.2 to 1.9)
Vomiting: Moderate0.1 (0.0 to 0.5)0.2 (0.0 to 1.0)
Vomiting: Severe0.0 (0.0 to 0.3)0.0 (0.0 to 0.7)
Diarrhea: Mild6.9 (5.6 to 8.3)6.0 (4.2 to 8.4)
Diarrhea: Moderate1.4 (0.8 to 2.1)2.4 (1.3 to 4.1)
Diarrhea: Severe0.0 (0.0 to 0.3)0.0 (0.0 to 0.7)
Muscle Pain: Mild10.0 (8.5 to 11.7)10.0 (7.6 to 12.8)
Muscle Pain: Moderate11.9 (10.3 to 13.7)11.5 (8.9 to 14.5)
Muscle Pain: Severe0.8 (0.4 to 1.4)0.8 (0.2 to 1.9)
Joint Pain: Mild9.6 (8.1 to 11.2)7.9 (5.7 to 10.5)
Joint Pain: Moderate8.3 (6.9 to 9.8)6.8 (4.8 to 9.2)
Joint Pain: Severe0.4 (0.2 to 0.9)0.9 (0.3 to 2.2)
PrimaryPercentage of Participants With Use of Antipyretic Medication Within 7 Days After Vaccination 1: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)

The use of antipyretic medication was recorded by participants in an e-diary for 7 days after vaccination. Exact 2-sided CI was based on the Clopper and Pearson method.

Time frame:
Within 7 days after Vaccination 1
Reported as:
Number · Percentage of participants
Percentage of Participants With Use of Antipyretic Medication Within 7 Days After Vaccination 1: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)
Percentage of participantsGroups 1+3+5+7 Combined MenABCWY + SalineGroups 2+4+6+8 Combined Trumenba + MenACWY-CRM
Percentage of Participants With Use of Antipyretic Medication Within 7 Days After Vaccination 1: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)29.5 (27.4 to 31.7)28.1 (24.6 to 31.7)
PrimaryPercentage of Participants With Use of Antipyretic Medication Within 7 Days After Vaccination 2: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)

The use of antipyretic medication recorded by participants in an e-diary for 7 days after vaccination. Exact 2-sided CI was based on the Clopper and Pearson method.

Time frame:
Within 7 days after Vaccination 2
Reported as:
Number · Percentage of participants
Percentage of Participants With Use of Antipyretic Medication Within 7 Days After Vaccination 2: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)
Percentage of participantsGroups 1+3+5+7 Combined MenABCWY + SalineGroups 2+4+6+8 Combined Trumenba + MenACWY-CRM
Percentage of Participants With Use of Antipyretic Medication Within 7 Days After Vaccination 2: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)25.1 (22.9 to 27.4)20.5 (17.1 to 24.2)
PrimaryPercentage of Participants With Adverse Events (AEs) Within 30 Days After Vaccination 1: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)

An AE was any untoward medical occurrence in a participant, temporally associated with the use of investigational product, whether or not considered related to the investigational product. Exact 2-sided CI was based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.

Time frame:
Within 30 days after Vaccination 1
Reported as:
Number · Percentage of participants
Percentage of Participants With Adverse Events (AEs) Within 30 Days After Vaccination 1: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)
Percentage of participantsGroups 1+3+5+7 Combined MenABCWY + SalineGroups 2+4+6+8 Combined Trumenba + MenACWY-CRM
Percentage of Participants With Adverse Events (AEs) Within 30 Days After Vaccination 1: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)5.8 (4.7 to 7.0)6.5 (4.7 to 8.6)
PrimaryPercentage of Participants With AEs Within 30 Days After Vaccination 2: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)

An AE was any untoward medical occurrence in a participant, temporally associated with the use of investigational product, whether or not considered related to the investigational product. Exact 2-sided CI was based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.

Time frame:
Within 30 days after Vaccination 2
Reported as:
Number · Percentage of participants
Percentage of Participants With AEs Within 30 Days After Vaccination 2: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)
Percentage of participantsGroups 1+3+5+7 Combined MenABCWY + SalineGroups 2+4+6+8 Combined Trumenba + MenACWY-CRM
Percentage of Participants With AEs Within 30 Days After Vaccination 2: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)5.3 (4.3 to 6.6)3.7 (2.3 to 5.7)
PrimaryPercentage of Participants With AEs Within 30 Days After Any Vaccination: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)

An AE was any untoward medical occurrence in a participant, temporally associated with the use of investigational product, whether or not considered related to the investigational product. Exact 2-sided CI was based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.

Time frame:
Within 30 days after any vaccination
Reported as:
Number · Percentage of participants
Percentage of Participants With AEs Within 30 Days After Any Vaccination: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)
Percentage of participantsGroups 1+3+5+7 Combined MenABCWY + SalineGroups 2+4+6+8 Combined Trumenba + MenACWY-CRM
Percentage of Participants With AEs Within 30 Days After Any Vaccination: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)9.7 (8.4 to 11.2)9.1 (7.0 to 11.6)
PrimaryPercentage of Participants With AEs During Vaccination Phase: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)

An AE was any untoward medical occurrence in a participant, temporally associated with the use of investigational product, whether or not considered related to the investigational product. Exact 2-sided CI was based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.

Time frame:
From day of Vaccination 1 (Day 1) up to 1 month after Vaccination 2 (approximately 7 months)
Reported as:
Number · Percentage of participants
Percentage of Participants With AEs During Vaccination Phase: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)
Percentage of participantsGroups 1+3+5+7 Combined MenABCWY + SalineGroups 2+4+6+8 Combined Trumenba + MenACWY-CRM
Percentage of Participants With AEs During Vaccination Phase: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)20.9 (19.0 to 22.8)20.3 (17.3 to 23.6)
PrimaryPercentage of Participants With Serious Adverse Events (SAEs) Within 30 Days After Vaccination 1: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)

An SAE was any untoward medical occurrence that, at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent disability/incapacity; congenital anomaly/birth defect and other important medical events. Exact 2-sided CI was based on the Clopper and Pearson method.

Time frame:
Within 30 days after Vaccination 1
Reported as:
Number · Percentage of participants
Percentage of Participants With Serious Adverse Events (SAEs) Within 30 Days After Vaccination 1: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)
Percentage of participantsGroups 1+3+5+7 Combined MenABCWY + SalineGroups 2+4+6+8 Combined Trumenba + MenACWY-CRM
Percentage of Participants With Serious Adverse Events (SAEs) Within 30 Days After Vaccination 1: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)0.06 (0.0 to 0.3)0.0 (0.0 to 0.6)
PrimaryPercentage of Participants With SAEs Within 30 Days After Vaccination 2: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)

An SAE was any untoward medical occurrence that, at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent disability/incapacity; congenital anomaly/birth defect and other important medical events. Exact 2-sided CI was based on the Clopper and Pearson method.

Time frame:
Within 30 days after Vaccination 2
Reported as:
Number · Percentage of participants
Percentage of Participants With SAEs Within 30 Days After Vaccination 2: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)
Percentage of participantsGroups 1+3+5+7 Combined MenABCWY + SalineGroups 2+4+6+8 Combined Trumenba + MenACWY-CRM
Percentage of Participants With SAEs Within 30 Days After Vaccination 2: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)0.1 (0.0 to 0.5)0.0 (0.0 to 0.7)
PrimaryPercentage of Participants With SAEs Within 30 Days After Any Vaccination: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)

An SAE was any untoward medical occurrence that, at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent disability/ incapacity; congenital anomaly/birth defect and other important medical events. Exact 2-sided CI was based on the Clopper and Pearson method.

Time frame:
Within 30 days after any vaccination
Reported as:
Number · Percentage of participants
Percentage of Participants With SAEs Within 30 Days After Any Vaccination: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)
Percentage of participantsGroups 1+3+5+7 Combined MenABCWY + SalineGroups 2+4+6+8 Combined Trumenba + MenACWY-CRM
Percentage of Participants With SAEs Within 30 Days After Any Vaccination: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)0.2 (0.0 to 0.5)0.0 (0.0 to 0.6)
PrimaryPercentage of Participants With SAEs During Vaccination Phase: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)

An SAE was any untoward medical occurrence that, at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent disability/ incapacity; congenital anomaly/birth defect and other important medical events. Exact 2-sided CI was based on the Clopper and Pearson method.

Time frame:
From day of Vaccination 1 (Day 1) up to 1 month after Vaccination 2 (approximately 7 months)
Reported as:
Number · Percentage of participants
Percentage of Participants With SAEs During Vaccination Phase: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)
Percentage of participantsGroups 1+3+5+7 Combined MenABCWY + SalineGroups 2+4+6+8 Combined Trumenba + MenACWY-CRM
Percentage of Participants With SAEs During Vaccination Phase: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)0.4 (0.2 to 0.8)0.0 (0.0 to 0.6)
PrimaryPercentage of Participants With SAEs During Follow-up Phase: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)

An SAE was any untoward medical occurrence that, at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent disability/ incapacity; congenital anomaly/birth defect and other important medical events. Exact 2-sided CI was based on the Clopper and Pearson method.

Time frame:
From 1 month after Vaccination 2 up to 6 months after Vaccination 2 (approximately 5 months)
Reported as:
Number · Percentage of participants
Percentage of Participants With SAEs During Follow-up Phase: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)
Percentage of participantsGroups 1+3+5+7 Combined MenABCWY + SalineGroups 2+4+6+8 Combined Trumenba + MenACWY-CRM
Percentage of Participants With SAEs During Follow-up Phase: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)0.3 (0.1 to 0.7)0.8 (0.2 to 2.0)
PrimaryPercentage of Participants With SAEs Throughout the Study: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)

An SAE was any untoward medical occurrence that, at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent disability/ incapacity; congenital anomaly/birth defect and other important medical events. Exact 2-sided CI was based on the Clopper and Pearson method.

Time frame:
From day of Vaccination 1 (Day 1) up to 6 months after Vaccination 2 (approximately 12 months)
Reported as:
Number · Percentage of participants
Percentage of Participants With SAEs Throughout the Study: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)
Percentage of participantsGroups 1+3+5+7 Combined MenABCWY + SalineGroups 2+4+6+8 Combined Trumenba + MenACWY-CRM
Percentage of Participants With SAEs Throughout the Study: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)0.6 (0.3 to 1.1)0.6 (0.2 to 1.6)
PrimaryPercentage of Participants With Medically Attended Adverse Events (MAEs) Within 30 Days After Vaccination 1: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)

MAE was defined as a non-serious AE that resulted in an evaluation at a medical facility. Exact 2-sided CI was based on the Clopper and Pearson method.

Time frame:
Within 30 days after Vaccination 1
Reported as:
Number · Percentage of participants
Percentage of Participants With Medically Attended Adverse Events (MAEs) Within 30 Days After Vaccination 1: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)
Percentage of participantsGroups 1+3+5+7 Combined MenABCWY + SalineGroups 2+4+6+8 Combined Trumenba + MenACWY-CRM
Percentage of Participants With Medically Attended Adverse Events (MAEs) Within 30 Days After Vaccination 1: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)3.6 (2.8 to 4.5)4.3 (2.9 to 6.2)
PrimaryPercentage of Participants With MAEs Within 30 Days After Vaccination 2: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)

MAE was defined as a non-serious AE that resulted in an evaluation at a medical facility. Exact 2-sided CI was based on the Clopper and Pearson method.

Time frame:
Within 30 days after Vaccination 2
Reported as:
Number · Percentage of participants
Percentage of Participants With MAEs Within 30 Days After Vaccination 2: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)
Percentage of participantsGroups 1+3+5+7 Combined MenABCWY + SalineGroups 2+4+6+8 Combined Trumenba + MenACWY-CRM
Percentage of Participants With MAEs Within 30 Days After Vaccination 2: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)3.6 (2.7 to 4.6)2.8 (1.6 to 4.6)
PrimaryPercentage of Participants With MAEs Within 30 Days After Any Vaccination: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)

MAE was defined as a non-serious AE that resulted in an evaluation at a medical facility. Exact 2-sided CI was based on the Clopper and Pearson method.

Time frame:
Within 30 days after any vaccination
Reported as:
Number · Percentage of participants
Percentage of Participants With MAEs Within 30 Days After Any Vaccination: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)
Percentage of participantsGroups 1+3+5+7 Combined MenABCWY + SalineGroups 2+4+6+8 Combined Trumenba + MenACWY-CRM
Percentage of Participants With MAEs Within 30 Days After Any Vaccination: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)6.3 (5.2 to 7.5)6.3 (4.6 to 8.5)
PrimaryPercentage of Participants With MAEs During Vaccination Phase: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)

MAE was defined as a non-serious AE that resulted in an evaluation at a medical facility. Exact 2-sided CI was based on the Clopper and Pearson method.

Time frame:
From day of Vaccination 1 (Day 1) up to 1 month after Vaccination 2 (approximately 7 months)
Reported as:
Number · Percentage of participants
Percentage of Participants With MAEs During Vaccination Phase: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)
Percentage of participantsGroups 1+3+5+7 Combined MenABCWY + SalineGroups 2+4+6+8 Combined Trumenba + MenACWY-CRM
Percentage of Participants With MAEs During Vaccination Phase: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)14.9 (13.3 to 16.7)14.3 (11.7 to 17.3)
PrimaryPercentage of Participants With MAEs During Follow-up Phase: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)

MAE was defined as a non-serious AE that resulted in an evaluation at a medical facility. Exact 2-sided CI was based on the Clopper and Pearson method.

Time frame:
From 1 month after Vaccination 2 up to 6 months after Vaccination 2 (approximately 5 months)
Reported as:
Number · Percentage of participants
Percentage of Participants With MAEs During Follow-up Phase: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)
Percentage of participantsGroups 1+3+5+7 Combined MenABCWY + SalineGroups 2+4+6+8 Combined Trumenba + MenACWY-CRM
Percentage of Participants With MAEs During Follow-up Phase: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)9.3 (7.8 to 10.9)7.5 (5.3 to 10.1)
PrimaryPercentage of Participants With MAEs Throughout the Study: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)

MAE was defined as a non-serious AE that resulted in an evaluation at a medical facility. Exact 2-sided CI was based on the Clopper and Pearson method.

Time frame:
From day of Vaccination 1 (Day 1) up to 6 months after Vaccination 2 (approximately 12 months)
Reported as:
Number · Percentage of participants
Percentage of Participants With MAEs Throughout the Study: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)
Percentage of participantsGroups 1+3+5+7 Combined MenABCWY + SalineGroups 2+4+6+8 Combined Trumenba + MenACWY-CRM
Percentage of Participants With MAEs Throughout the Study: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)19.3 (17.5 to 21.2)18.3 (15.4 to 21.5)
PrimaryPercentage of Participants With Newly Diagnosed Chronic Medical Condition (NDCMC) Within 30 Days After Vaccination 1: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)

An NDCMC was defined as a disease or medical condition, not previously identified, that is expected to be persistent or otherwise long-lasting in its effects. Exact 2-sided CI was based on the Clopper and Pearson method.

Time frame:
Within 30 days after Vaccination 1
Reported as:
Number · Percentage of participants
Percentage of Participants With Newly Diagnosed Chronic Medical Condition (NDCMC) Within 30 Days After Vaccination 1: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)
Percentage of participantsGroups 1+3+5+7 Combined MenABCWY + SalineGroups 2+4+6+8 Combined Trumenba + MenACWY-CRM
Percentage of Participants With Newly Diagnosed Chronic Medical Condition (NDCMC) Within 30 Days After Vaccination 1: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)0.2 (0.1 to 0.6)0.0 (0.0 to 0.6)
PrimaryPercentage of Participants With NDCMC Within 30 Days After Vaccination 2: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)

An NDCMC was defined as a disease or medical condition, not previously identified, that is expected to be persistent or otherwise long-lasting in its effects. Exact 2-sided CI was based on the Clopper and Pearson method.

Time frame:
Within 30 days after Vaccination 2
Reported as:
Number · Percentage of participants
Percentage of Participants With NDCMC Within 30 Days After Vaccination 2: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)
Percentage of participantsGroups 1+3+5+7 Combined MenABCWY + SalineGroups 2+4+6+8 Combined Trumenba + MenACWY-CRM
Percentage of Participants With NDCMC Within 30 Days After Vaccination 2: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)0.06 (0.0 to 0.4)0.0 (0.0 to 0.7)
PrimaryPercentage of Participants With NDCMC Within 30 Days After Any Vaccination: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)

An NDCMC was defined as a disease or medical condition, not previously identified, that is expected to be persistent or otherwise long-lasting in its effects. Exact 2-sided CI was based on the Clopper and Pearson method.

Time frame:
Within 30 Days after any vaccination
Reported as:
Number · Percentage of participants
Percentage of Participants With NDCMC Within 30 Days After Any Vaccination: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)
Percentage of participantsGroups 1+3+5+7 Combined MenABCWY + SalineGroups 2+4+6+8 Combined Trumenba + MenACWY-CRM
Percentage of Participants With NDCMC Within 30 Days After Any Vaccination: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)0.3 (0.1 to 0.7)0.0 (0.0 to 0.6)
PrimaryPercentage of Participants With NDCMC During Vaccination Phase: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)

An NDCMC was defined as a disease or medical condition, not previously identified, that is expected to be persistent or otherwise long-lasting in its effects. Exact 2-sided CI was based on the Clopper and Pearson method.

Time frame:
From day of Vaccination 1 (Day 1) up to 1 month after Vaccination 2 (approximately 7 months)
Reported as:
Number · Percentage of participants
Percentage of Participants With NDCMC During Vaccination Phase: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)
Percentage of participantsGroups 1+3+5+7 Combined MenABCWY + SalineGroups 2+4+6+8 Combined Trumenba + MenACWY-CRM
Percentage of Participants With NDCMC During Vaccination Phase: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)1.1 (0.7 to 1.7)0.3 (0.0 to 1.1)
PrimaryPercentage of Participants With NDCMC During Follow-up Phase: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)

An NDCMC was defined as a disease or medical condition, not previously identified, that is expected to be persistent or otherwise long-lasting in its effects. Exact 2-sided CI was based on the Clopper and Pearson method.

Time frame:
From 1 month after Vaccination 2 up to 6 months after Vaccination 2 (approximately 5 months)
Reported as:
Number · Percentage of participants
Percentage of Participants With NDCMC During Follow-up Phase: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)
Percentage of participantsGroups 1+3+5+7 Combined MenABCWY + SalineGroups 2+4+6+8 Combined Trumenba + MenACWY-CRM
Percentage of Participants With NDCMC During Follow-up Phase: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)0.4 (0.1 to 0.8)0.0 (0.0 to 0.7)
PrimaryPercentage of Participants With NDCMC Throughout the Study: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)

An NDCMC was defined as a disease or medical condition, not previously identified, that is expected to be persistent or otherwise long-lasting in its effects. Exact 2-sided CI was based on the Clopper and Pearson method.

Time frame:
From day of Vaccination 1 (Day 1) up to 6 months after Vaccination 2 (approximately 12 months)
Reported as:
Number · Percentage of participants
Percentage of Participants With NDCMC Throughout the Study: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)
Percentage of participantsGroups 1+3+5+7 Combined MenABCWY + SalineGroups 2+4+6+8 Combined Trumenba + MenACWY-CRM
Percentage of Participants With NDCMC Throughout the Study: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)1.4 (0.9 to 2.1)0.3 (0.0 to 1.1)
PrimaryPercentage of Participants With Immediate AE Within 30 Minutes After Vaccination 1: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)

Immediate AEs were defined as AEs occurring within the first 30 minutes after investigational product administration. Exact 2-sided CI was based on the Clopper and Pearson method.

Time frame:
Within 30 minutes after Vaccination 1
Reported as:
Number · Percentage of participants
Percentage of Participants With Immediate AE Within 30 Minutes After Vaccination 1: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)
Percentage of participantsGroups 1+3+5+7 Combined MenABCWY + SalineGroups 2+4+6+8 Combined Trumenba + MenACWY-CRM
Percentage of Participants With Immediate AE Within 30 Minutes After Vaccination 1: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)0 (NA to NA)0 (NA to NA)
PrimaryPercentage of Participants With Immediate AE Within 30 Minutes After Vaccination 2: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)

Immediate AEs were defined as AEs occurring within the first 30 minutes after investigational product administration. Exact 2-sided CI was based on the Clopper and Pearson method.

Time frame:
Within 30 minutes after Vaccination 2
Reported as:
Number · Percentage of participants
Percentage of Participants With Immediate AE Within 30 Minutes After Vaccination 2: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)
Percentage of participantsGroups 1+3+5+7 Combined MenABCWY + SalineGroups 2+4+6+8 Combined Trumenba + MenACWY-CRM
Percentage of Participants With Immediate AE Within 30 Minutes After Vaccination 2: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)0 (NA to NA)0 (NA to NA)
PrimaryPercentage of Participants Who Missed Days of School or Work Due to AEs During Vaccination Phase: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)

An AE was any untoward medical occurrence in a participant, temporally associated with the use of investigational product, whether or not considered related to the investigational product. Percentage of participants who missed days of school or work due to AEs during vaccination phase were reported in this outcome measure.

Time frame:
From day of Vaccination 1 (Day 1) up to 1 month after Vaccination 2 (approximately 7 months)
Reported as:
Number · Percentage of participants
Percentage of Participants Who Missed Days of School or Work Due to AEs During Vaccination Phase: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)
Percentage of participantsGroups 1+3+5+7 Combined MenABCWY + SalineGroups 2+4+6+8 Combined Trumenba + MenACWY-CRM
Percentage of Participants Who Missed Days of School or Work Due to AEs During Vaccination Phase: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)5.04.5
SecondaryPercentage of Participants Achieving At Least 4-Fold Rise in hSBA Titer From Baseline for Each MenACWY Test Strains: 1 Month After Vaccination 1 in Group 1 Compared to Group 2

4-fold increase was defined as: 1) for participants with baseline hSBA titer below LOD (or hSBA titer \<1:4), 4-fold rise was defined as hSBA titer \>=1:16; 2) baseline hSBA titer \>=LOD (i.e., hSBA titer of \>=1:4) and \< LLOQ (i.e. hSBA titer of 1:8), 4-fold rise was defined as hSBA titer \>=4times LLOQ; 3) baseline hSBA titer \>=LLOQ, 4-fold rise was defined as hSBA titer \>=4 times baseline titer. Exact 2-sided CI using Clopper and Pearson method was presented.

Time frame:
Baseline (pre-vaccination on Day 1), 1 month after Vaccination 1
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving At Least 4-Fold Rise in hSBA Titer From Baseline for Each MenACWY Test Strains: 1 Month After Vaccination 1 in Group 1 Compared to Group 2
Percentage of participantsACWY-Naive: Group 1 MenABCWY + Saline (Immunogenicity and Safety Set)ACWY-Naive: Group 2 Trumenba+ MenACWY - CRM (Immunogenicity and Safety Set)
MenA97.0 (95.1 to 98.3)95.3 (91.9 to 97.5)
MenC62.9 (58.5 to 67.1)52.4 (46.0 to 58.7)
MenW79.3 (75.4 to 82.8)73.0 (66.9 to 78.4)
MenY82.0 (78.3 to 85.3)70.6 (64.5 to 76.2)
Statistical analysis
  • ACWY-Naive: Group 1 MenABCWY + Saline (Immunogenicity and Safety Set) vs ACWY-Naive: Group 2 Trumenba+ MenACWY - CRM (Immunogenicity and Safety Set) · Difference in percentage of participants: 1.7 · 95% CI -1.0 to 5.3
  • ACWY-Naive: Group 1 MenABCWY + Saline (Immunogenicity and Safety Set) vs ACWY-Naive: Group 2 Trumenba+ MenACWY - CRM (Immunogenicity and Safety Set) · Difference in percentage of participants: 10.5 · 95% CI 3.0 to 17.9
  • ACWY-Naive: Group 1 MenABCWY + Saline (Immunogenicity and Safety Set) vs ACWY-Naive: Group 2 Trumenba+ MenACWY - CRM (Immunogenicity and Safety Set) · Difference in percentage of participants: 6.3 · 95% CI -0.1 to 13.1
  • ACWY-Naive: Group 1 MenABCWY + Saline (Immunogenicity and Safety Set) vs ACWY-Naive: Group 2 Trumenba+ MenACWY - CRM (Immunogenicity and Safety Set) · Difference in percentage of participants: 11.4 · 95% CI 5.0 to 18.2
SecondaryPercentage of Participants Achieving At Least 4-Fold Rise in hSBA Titer From Baseline for Each MenACWY Test Strains: 1 Month After Vaccination 1 in Group 3 Compared to Group 4

4-fold increase was defined as: 1) for participants with baseline hSBA titer below LOD (or hSBA titer \<1:4), 4-fold rise was defined as hSBA titer \>=1:16; 2) baseline hSBA titer \>=LOD (i.e., hSBA titer of \>=1:4) and \< LLOQ (i.e. hSBA titer of 1:8), 4-fold rise was defined as hSBA titer \>=4 times LLOQ; 3) baseline hSBA titer \> =LLOQ, 4-fold rise was defined as hSBA titer \>=4 times baseline titer. Exact 2-sided CI using Clopper and Pearson method was presented.

Time frame:
Baseline (pre-vaccination on Day 1), 1 month after Vaccination 1
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving At Least 4-Fold Rise in hSBA Titer From Baseline for Each MenACWY Test Strains: 1 Month After Vaccination 1 in Group 3 Compared to Group 4
Percentage of participantsACWY-Experienced: Group 3 MenABCWY + Saline (Immunogenicity and Safety Set)ACWY-Experienced: Group 4 Trumenba+ MenACWY - CRM (Immunogenicity and Safety Set)
MenA94.8 (92.2 to 96.7)96.9 (93.7 to 98.8)
MenC93.4 (90.7 to 95.5)94.7 (90.9 to 97.2)
MenW97.4 (95.4 to 98.7)96.4 (93.0 to 98.4)
MenY94.3 (91.8 to 96.3)93.7 (89.7 to 96.5)
Statistical analysis
  • ACWY-Experienced: Group 3 MenABCWY + Saline (Immunogenicity and Safety Set) vs ACWY-Experienced: Group 4 Trumenba+ MenACWY - CRM (Immunogenicity and Safety Set) · Difference in percentage of participants: -2.2 · 95% CI -5.2 to 1.4
  • ACWY-Experienced: Group 3 MenABCWY + Saline (Immunogenicity and Safety Set) vs ACWY-Experienced: Group 4 Trumenba+ MenACWY - CRM (Immunogenicity and Safety Set) · Difference in percentage of participants: -1.3 · 95% CI -4.9 to 2.9
  • ACWY-Experienced: Group 3 MenABCWY + Saline (Immunogenicity and Safety Set) vs ACWY-Experienced: Group 4 Trumenba+ MenACWY - CRM (Immunogenicity and Safety Set) · Difference in percentage of participants: 1.0 · 95% CI -1.6 to 4.6
  • ACWY-Experienced: Group 3 MenABCWY + Saline (Immunogenicity and Safety Set) vs ACWY-Experienced: Group 4 Trumenba+ MenACWY - CRM (Immunogenicity and Safety Set) · Difference in percentage of participants: 0.6 · 95% CI -3.0 to 5.0

Adverse events

Collected over Local reactions and systemic events recorded using systematic assessment within 7 days after Vaccination 1 and 2; SAEs and all-cause mortality recorded using non-systematic assessment from Day 1 up to 6 months after vaccination 2 (approximately 12 months) and other AEs recorded using non-systematic assessment from Day 1 up to 1 month after vaccination 2 (approximately 7 months). Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ACWY-Naive: Group 1 MenABCWY + Saline (Immunogenicity and Safety Set)0/547 (0%)6/547 (1.1%)533/547 (97.4%)
ACWY-Naive: Group 2 Trumenba+ MenACWY - CRM (Immunogenicity and Safety Set)0/274 (0%)1/274 (0.4%)262/274 (95.6%)
ACWY-Experienced: Group 3 MenABCWY + Saline (Immunogenicity and Safety Set)0/526 (0%)3/526 (0.6%)504/526 (95.8%)
ACWY-Experienced: Group 4 Trumenba+ MenACWY - CRM (Immunogenicity and Safety Set)0/260 (0%)2/260 (0.8%)244/260 (93.8%)
ACWY-Naive: Group 5 MenABCWY + Saline (Safety Set)0/537 (0%)2/537 (0.4%)512/537 (95.3%)
ACWY-Naive: Group 6 Trumenba+ MenACWY - CRM (Safety Set)0/56 (0%)1/56 (1.8%)53/56 (94.6%)
ACWY-Experienced: Group 7 MenABCWY + Saline (Safety Set)0/153 (0%)0/153 (0%)148/153 (96.7%)
ACWY-Experienced: Group 8 Trumenba+ MenACWY - CRM (Safety Set)0/59 (0%)0/59 (0%)58/59 (98.3%)
Most frequent serious events
Showing 10 of 17
Most frequent serious events
EventACWY-Naive: Group 1 MenABCWY + Saline (Immunogenicity and Safety Set)ACWY-Naive: Group 2 Trumenba+ MenACWY - CRM (Immunogenicity and Safety Set)ACWY-Experienced: Group 3 MenABCWY + Saline (Immunogenicity and Safety Set)ACWY-Experienced: Group 4 Trumenba+ MenACWY - CRM (Immunogenicity and Safety Set)ACWY-Naive: Group 5 MenABCWY + Saline (Safety Set)ACWY-Naive: Group 6 Trumenba+ MenACWY - CRM (Safety Set)ACWY-Experienced: Group 7 MenABCWY + Saline (Safety Set)ACWY-Experienced: Group 8 Trumenba+ MenACWY - CRM (Safety Set)
OverdoseInjury, poisoning and procedural complications0/5470/2740/5260/2600/5371/560/1530/59
Escherichia urinary tract infectionInfections and infestations0/5470/2740/5261/2600/5370/560/1530/59
Status migrainosusNervous system disorders0/5470/2740/5261/2600/5370/560/1530/59
DepressionPsychiatric disorders2/5470/2740/5260/2600/5370/560/1530/59
AppendicitisInfections and infestations0/5471/2740/5260/2600/5370/560/1530/59
Gastroenteritis salmonellaInfections and infestations0/5470/2741/5260/2600/5370/560/1530/59
Post procedural haemorrhageInjury, poisoning and procedural complications0/5470/2741/5260/2600/5370/560/1530/59
Food intoleranceMetabolism and nutrition disorders0/5470/2741/5260/2600/5370/560/1530/59
Depression suicidalPsychiatric disorders0/5470/2741/5260/2600/5370/560/1530/59
Spinal cord injuryInjury, poisoning and procedural complications0/5470/2740/5260/2601/5370/560/1530/59
Most frequent other events
Showing 10 of 66
Most frequent other events
EventACWY-Naive: Group 1 MenABCWY + Saline (Immunogenicity and Safety Set)ACWY-Naive: Group 2 Trumenba+ MenACWY - CRM (Immunogenicity and Safety Set)ACWY-Experienced: Group 3 MenABCWY + Saline (Immunogenicity and Safety Set)ACWY-Experienced: Group 4 Trumenba+ MenACWY - CRM (Immunogenicity and Safety Set)ACWY-Naive: Group 5 MenABCWY + Saline (Safety Set)ACWY-Naive: Group 6 Trumenba+ MenACWY - CRM (Safety Set)ACWY-Experienced: Group 7 MenABCWY + Saline (Safety Set)ACWY-Experienced: Group 8 Trumenba+ MenACWY - CRM (Safety Set)
Injection site pain (PAIN AT INJECTION SITE)General disorders522/547247/274486/526228/260493/53751/56144/15357/59
Fatigue (FATIGUE)General disorders364/547183/274337/526160/260317/53730/5699/15343/59
Headache (HEADACHE)Nervous system disorders330/547152/274312/526161/260282/53724/5686/15337/59
Myalgia (MUSCLE PAIN)Musculoskeletal and connective tissue disorders198/54797/274207/52697/260167/53718/5657/15322/59
Swelling (SWELLING)General disorders186/54771/274158/52657/260200/53716/5649/15319/59
Erythema (REDNESS)Skin and subcutaneous tissue disorders183/54775/274162/52658/260190/53715/5639/15316/59
Chills (CHILLS)General disorders155/54778/274151/52659/260130/53714/5643/15319/59
Arthralgia (JOINT PAIN)Musculoskeletal and connective tissue disorders156/54775/274156/52683/260144/53712/5648/15319/59
Diarrhoea (DIARRHEA)Gastrointestinal disorders69/54750/274116/52654/26072/5378/5623/1538/59
Pyrexia (FEVER)General disorders44/54724/27429/52613/26042/5373/568/1533/59

Baseline characteristics

Safety population included all randomized participants who received at least 1 dose of investigational product and had safety data reported after vaccination. One participant initially randomized to group 3 was excluded from safety population set as the participant received the wrong vaccination (Trumenba + saline).

Age, Continuous
Age, Continuous(Years)ACWY-Naive: Group 1 MenABCWY + Saline (Immunogenicity and Safety Set)ACWY-Naive: Group 2 Trumenba+ MenACWY - CRM (Immunogenicity and Safety Set)ACWY-Experienced: Group 3 MenABCWY + Saline (Immunogenicity and Safety Set)ACWY-Experienced: Group 4 Trumenba+ MenACWY - CRM (Immunogenicity and Safety Set)ACWY-Naive: Group 5 MenABCWY + Saline (Safety Set)ACWY-Naive: Group 6 Trumenba+ MenACWY - CRM (Safety Set)ACWY-Experienced: Group 7 MenABCWY + Saline (Safety Set)ACWY-Experienced: Group 8 Trumenba+ MenACWY - CRM (Safety Set)Total
Mean16.7 ± 5.4916.7 ± 5.3917.3 ± 3.1717.4 ± 3.2813.5 ± 4.0513.5 ± 4.5017.1 ± 3.0416.0 ± 2.7516.1 ± 4.55
Sex: Female, Male
Sex: Female, Male(Participants)ACWY-Naive: Group 1 MenABCWY + Saline (Immunogenicity and Safety Set)ACWY-Naive: Group 2 Trumenba+ MenACWY - CRM (Immunogenicity and Safety Set)ACWY-Experienced: Group 3 MenABCWY + Saline (Immunogenicity and Safety Set)ACWY-Experienced: Group 4 Trumenba+ MenACWY - CRM (Immunogenicity and Safety Set)ACWY-Naive: Group 5 MenABCWY + Saline (Safety Set)ACWY-Naive: Group 6 Trumenba+ MenACWY - CRM (Safety Set)ACWY-Experienced: Group 7 MenABCWY + Saline (Safety Set)ACWY-Experienced: Group 8 Trumenba+ MenACWY - CRM (Safety Set)Total
Female2891402791312532096281236
Male2581342471292843657311176
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)ACWY-Naive: Group 1 MenABCWY + Saline (Immunogenicity and Safety Set)ACWY-Naive: Group 2 Trumenba+ MenACWY - CRM (Immunogenicity and Safety Set)ACWY-Experienced: Group 3 MenABCWY + Saline (Immunogenicity and Safety Set)ACWY-Experienced: Group 4 Trumenba+ MenACWY - CRM (Immunogenicity and Safety Set)ACWY-Naive: Group 5 MenABCWY + Saline (Safety Set)ACWY-Naive: Group 6 Trumenba+ MenACWY - CRM (Safety Set)ACWY-Experienced: Group 7 MenABCWY + Saline (Safety Set)ACWY-Experienced: Group 8 Trumenba+ MenACWY - CRM (Safety Set)Total
Hispanic or Latino935315686131155829621
Not Hispanic or Latino4502173661734054193301775
Unknown or Not Reported4441102016
Race (NIH/OMB)
Race (NIH/OMB)(Participants)ACWY-Naive: Group 1 MenABCWY + Saline (Immunogenicity and Safety Set)ACWY-Naive: Group 2 Trumenba+ MenACWY - CRM (Immunogenicity and Safety Set)ACWY-Experienced: Group 3 MenABCWY + Saline (Immunogenicity and Safety Set)ACWY-Experienced: Group 4 Trumenba+ MenACWY - CRM (Immunogenicity and Safety Set)ACWY-Naive: Group 5 MenABCWY + Saline (Safety Set)ACWY-Naive: Group 6 Trumenba+ MenACWY - CRM (Safety Set)ACWY-Experienced: Group 7 MenABCWY + Saline (Safety Set)ACWY-Experienced: Group 8 Trumenba+ MenACWY - CRM (Safety Set)Total
American Indian or Alaska Native2222412116
Asian194186711157
Native Hawaiian or Other Pacific Islander102010004
Black or African American26197432575275245
White46723937019541946103421881
More than one race93123722038
Unknown or Not Reported23748224211810171
08

Study locations

78 sites
  • Alabama Clinical Therapeutics, LLC, Birmington Pediatric Assocaites
    Birmingham, Alabama 35205, United States
  • Central Research Associates, Inc.
    Birmingham, Alabama 35205, United States
  • Fiel Family and Sports Medicine, PC/CCT Research
    Tempe, Arizona 85283, United States
  • Velocity Clinical Research (Banning)
    Banning, California 92220, United States
  • Madera Family Medical Group
    Madera, California 93637, United States
  • Center for Clinical Trials, LLC
    Paramount, California 90723, United States
  • Center for Clinical Trials
    Paramount, California 90723, United States
  • Optumcare Colorado Springs, LLC
    Colorado Springs, Colorado 80922, United States
  • ALL Medical Research, LLC
    Cooper City, Florida 33024, United States
  • Alliance for MultiSpecialty Research, LLC - Miami
    Coral Gables, Florida 33134, United States
  • Health Awareness, Inc.
    Jupiter, Florida 33458, United States
  • Altus Research
    Lake Worth, Florida 33461, United States
  • Crystal Biomedical Research, LLC
    Miami Lakes, Florida 33014, United States
  • San Marcus Research Clinic, Inc.
    Miami Lakes, Florida 33014, United States
  • Acevedo Clinical Research Associates
    Miami, Florida 33142, United States
  • Healthy Life Research, Inc.
    Miami, Florida 33175, United States
  • Bio-Medical Research, LLC
    Miami, Florida 33184, United States
  • Complete Health Research
    Ormond Beach, Florida 32174, United States
  • Oviedo Medical Research, LLC
    Oviedo, Florida 32765, United States
  • PAS Research
    Tampa, Florida 33613, United States
  • Tekton Research, Inc.
    Chamblee, Georgia 30341, United States
  • Velocity Clinical Research - Boise
    Meridian, Idaho 83642, United States
  • Saltzer Health
    Nampa, Idaho 83686, United States
  • MOC Research
    Mishawaka, Indiana 46544, United States
  • The South Bend Clinic Center for Research
    South Bend, Indiana 46617, United States
  • The Iowa Clinic
    Ankeny, Iowa 50023, United States
  • The Iowa Clinic
    West Des Moines, Iowa 50266, United States
  • Alliance for Multispecialty Research, LLC
    El Dorado, Kansas 67042, United States
  • Alliance for Multispecialty Research, LLC
    Newton, Kansas 67114, United States
  • Michael W. Simon, MD, PSC
    Lexington, Kentucky 40517, United States
  • Meridian Clinical Research, LLC
    Baton Rouge, Louisiana 70806, United States
  • Meridian Clinical Research, LLC
    Baton Rouge, Louisiana 70809, United States
  • Acorn to Oak Pediatrics - ACC Pediatric Research
    Haughton, Louisiana 71037, United States
  • Sundance Clinical Research, LLC
    Saint Louis, Missouri 63141, United States
  • Skyline Medical Center, PC/CCT Research
    Elkhorn, Nebraska 68022, United States
  • Quality Clinical Research
    Omaha, Nebraska 68114, United States
  • Meridian Clinical Research, LLC
    Binghamton, New York 13901, United States
  • PMG Research of Salisbury, LLC
    Salisbury, North Carolina 28144, United States
  • PMG Research of Wilmington, LLC
    Wilmington, North Carolina 28401, United States
  • Accellacare - Winston-Salem
    Winston-Salem, North Carolina 27103, United States
  • PMG Research of Winston-Salem, LLC
    Winston-Salem, North Carolina 27103, United States
  • Velocity Clinical Research - Cleveland
    Cleveland, Ohio 44122, United States
  • Dayton Clinical Research
    Dayton, Ohio 45409, United States
  • Pediatric Associates of Fairfield, Inc.
    Fairfield, Ohio 45014, United States
  • Senders Pediatrics
    South Euclid, Ohio 44121, United States
  • Lynn Institute of Norman
    Norman, Oklahoma 73072, United States
  • Tekton Research
    Yukon, Oklahoma 73099, United States
  • Liberty Family Practice
    Erie, Pennsylvania 16508, United States
  • Thomas Jefferson University
    Philadelphia, Pennsylvania 19107, United States
  • Accellacare US Inc.
    Mount Pleasant, South Carolina 29464, United States
  • Internal Medicine and Pediatric Associates of Bristol, PC
    Bristol, Tennessee 37620, United States
  • Holston Medical Group
    Kingsport, Tennessee 37660, United States
  • Family Medicine Associates of Texas
    Carrollton, Texas 75010, United States
  • AIM Trials, LLC
    Plano, Texas 75093, United States
  • North Texas Family Medicine
    Plano, Texas 75093, United States
  • Tekton Research
    San Antonio, Texas 78229, United States
  • Olympus Family Medicine/CCT Research
    Holladay, Utah 84117, United States
  • Pediatric Care
    Provo, Utah 84604, United States
  • J. Lewis Research, Inc. / Foothill Family Clinic
    Salt Lake City, Utah 84109, United States
  • J. Lewis Research, Inc. / Foothill Family Clinic South
    Salt Lake City, Utah 84121, United States
  • J. Lewis Research, Inc. / Jordan River Family Medicine
    South Jordan, Utah 84095, United States
  • SANARE s.r.o
    Ceske Budejovice, 37006, Czechia
  • Fakultni nemocnice Hradec Kralove
    Hradec Kralove, 50005, Czechia
  • Ordinace praktickeho lekare pro deti a dorost
    Jindrichuv Hradec, 377 01, Czechia
  • MUDr. Katerina Stichhauerova s.r.o.
    Pardubice, 530 03, Czechia
  • Medicentrum 6 s.r.o.
    Praha 6, 160 00, Czechia
  • Praktik Pb s.r.o.
    Pribram, 26101, Czechia
  • Aarhus Universitetshospital
    Aarhus N, 8200, Denmark
  • DRC Gyógyszervizsgáló Központ Kft.
    Balatonfüred, 8230, Hungary
  • ClinTrial Audit Kft., Klinikai Farmakologiai Intezet, Vedooltasi Ambulancia
    Debrecen, 4031, Hungary
  • Coronella Orvosi Centrum / Trial Pharma Kft.
    Gyula, 5700, Hungary
  • CRU Hungary Kft.
    Miskolc, 3529, Hungary
  • Fejér Megyei Szent György Egyetemi Oktató Kórház
    Székesfehérvár, 8000, Hungary
  • Centrum Badan Klinicznych JCI
    Krakow, 30-348, Poland
  • Przylądek Zdrowia
    Krakow, 30-644, Poland
  • Niepubliczny Zaklad Opieki Zdrowotnej "Salmed"
    Leczna, 21-010, Poland
  • Niepubliczny Zaklad Lecznictwa Ambulatoryjnego MICHALKOWICE
    Siemianowice Slaskie, 41-103, Poland
  • Szpital im. Sw. Jadwigi Slaskiej w Trzebnicy
    Trzebnica, 55-100, Poland
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2020 to primary completion in Jul 2022, 25 months.

Results were first posted in Apr 2023, 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 15, 2020
First posted
Jun 19, 2020
StartActual
Jun 17, 2020
Primary completionActual
Jul 24, 2022
CompletionActual
Jul 24, 2022
Results first posted
Apr 18, 2023
Last update
Apr 18, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04440163
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Jun 19, 2020
Start date
Jun 17, 2020
Primary completion
Jul 24, 2022
Completion
Jul 24, 2022
Results posted
Apr 18, 2023
Last update
Apr 18, 2023

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Meningococcal pentavalent vaccine · MenB-FHbp vaccine · 4CMenB vaccine

Start the discussion